Health Care/Hospital

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

2026-02-16 22:03 782

QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio

Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to exp...

2026-02-16 14:00 1111

Community Med Care's "Love & Share" CNY Blessing Campaign Gives the Gift of TCM Healing and Brings Hope to Children in Need

HONG KONG, Feb. 16, 2026 /PRNewswire/ -- This Lunar New Year, Community Med Care is turning seasonal blessings into lasting impact. The charity's "Love & Share" CNY Blessing Campaign invites the public to support its flagship program, "Stand Up with Love: Angel Mission", which provides free Tradi...

2026-02-16 09:00 2664

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...

2026-02-16 08:10 2548

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of ...

2026-02-14 20:58 4915

Visa-Free Policies Fuel New Trend in Medical Tourism: International Patients Praise Parkway in Shanghai

SHANGHAI, Feb. 14, 2026 /PRNewswire/ -- With the implementation of 144-hour visa-free transit across multiple cities in China, international visitors now enjoy significantly greater convenience. Recently, an intriguing trend has emerged: many foreign nationals arriving in Shanghai for business or...

2026-02-14 20:12 4920

SingHealth Opens Community MRI Centre at Dunearn Village in Collaboration with United Imaging

SINGAPORE, Feb. 14, 2026 /PRNewswire/ -- SingHealth, Singapore's largest public healthcare cluster, has opened a new MRI centre at Dunearn Village, marking its first MRI facility located outside a hospital campus and extending diagnostic imaging services into the community. Developed in collabor...

2026-02-14 20:00 2770

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases,...

2026-02-13 14:04 2500

Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the...

2026-02-13 14:00 2480

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2026-02-13 08:00 2354

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/...

2026-02-13 08:00 4717

SleepAI.com Introduces an AI-Powered Sleep and Emotional Wellness Platform for Modern Life

LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- SleepAI.com, a personalized AI sleep companion, today announced the launch of an AI-powered sleep and emotional wellness platform, now available on both the iOS and Google Play app stores. The platform is designed to address one of modern life's most per...

2026-02-13 02:00 2272

Datasea Reports Second Fiscal Quarter 2026 Results

Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...

2026-02-12 22:20 5841

Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...

2026-02-12 22:00 2432

Ubie Announces Collaboration to Reinvent the Healthcare Digital Front Door

* Ubie and Mayo Clinic collaborate with the goal of delivering a unified, AI-powered chat and voice platform to streamline healthcare access, reduce complexity and offer a best-in-class patient experience * Natural conversations, instant answers, and a seamless triage-to-booking flow will dri...

2026-02-12 22:00 2390

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

* Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) in...

2026-02-12 20:00 2398

First clinical success! Yuanhua Tech, with its orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, breaks into the high-end medical equipment market

HONG KONG, Feb. 12, 2026 /PRNewswire/ -- On February 11, the orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, which was 100% homemade by Yuanhua Robotics, Perception and AI Technologies Ltd. (hereinafter referred to as "Yuanhua Tech"), saw its first clinic...

2026-02-12 19:34 2192

EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai

DUBAI, UAE, Feb. 12, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical dis...

2026-02-12 17:27 2819

Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. Th...

2026-02-12 16:00 3051

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Associa...

2026-02-12 15:01 2387
12345 ... 858